Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Karine Léveillé
Observed names:
K. Leveille,
Karine Leveille,
Karine Leveillé
Institutions:
Centre Hospitalier Universitaire Sainte-Justine,
CHU Sainte-Justine Research Center
Observed institutions:
Centre Hospitalier Universitaire Sainte-Justine,
CHU Sainte-Justine Research Center,
Université de Montréal
ORCID:
0009-0000-6283-5888
Observed ORCID:
0009-0000-6283-5888
OpenAlex ID:
A5031041683
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
2021
·
Philippe Bégin
, Jeannie Callum
, et al.
·
Nature Medicine
·
277
PDF
Prime Editing for p47 phox -Deficient Chronic Granulomatous Disease
2025
·
Jennifer L. Gori
, Elie Haddad
, et al.
·
New England Journal of Medicine
·
43
PDF
Rapid clinical and transcriptomic response to anifrolumab in refractory anti-TIF1γ–positive juvenile dermatomyositis
2025
·
Clément Triaille
, Maryam Piram
, et al.
·
Annals of the Rheumatic Diseases
·
10
Author Correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
2022
·
Philippe Bégin
, Jeannie Callum
, et al.
·
Nature Medicine
·
4
PDF
Functional stratification of MEFV variants by flow cytometric assessment of pyrin inflammasome activation
2026
·
Blandine Monjarret
, Isabel Fernandez
, et al.
·
Pediatric Allergy and Immunology
·
1
PDF
Implementing a First-in-Human Clinical Trial of Prime-Editing Gene Therapy in p47-CGD: Clinical Data and Site Perspectives
2026
·
K. Leveille
, J.L. Gori
, et al.
·
Journal of Human Immunity
·
1
First in human prime edited autologous hematopoietic stem cell therapy for the treatment of p47phox CGD: Initial results of PRIME-0101
2025
·
Elie Haddad
, Haydar Frangoul
, et al.
·
Blood
·
1
PDF
Reply to: Concerns about estimating relative risk of death associated with convalescent plasma for COVID-19
2022
·
Philippe Bégin
, Jeannie Callum
, et al.
·
Nature Medicine
·
1
Defining the window of opportunity for post-transplant ThINKK therapy and TRAIL as a biomarker of NK cell response
2026
·
Émilie Ollame-Omvane
, Leila Ben Khemis
, et al.
·
Cytotherapy
PDF
Show more works
View as search
Works count:
9
Citation count:
338
H-index:
4
I10-index:
3
Year
Topic
Type